Evaluation of the cellular immunity in patients coinfected by the hepatitis C virus and the human immunodeficiency virus;Avaliação da imunidade celular nos pacientes co-infectados pelo vírus da hepatite C e vírus da imunodeficiência humana

Arquivos de Gastroenterologia

Volumn 44, Issue 2, 2007, Pages 113-117

  Valle Tovo, Cristiane ^a,c   Dos Santos, Diogo Edele ^b   De Mattos, Angelo Zambam ^b   De Mattos, Angelo Alves ^b   Santos, Breno Riegel ^a   Galperim, Bruno ^a  

^a HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^b Department of Pathology

^c NONE   (Brazil)

Author keywords

Cellular; Hepacivirus; HIV; Immunity

Indexed keywords

ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DEMOGRAPHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE SYSTEM; VIRUS LOAD;

EID: 35649006893     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032007000200005     Document Type: Article

References (34)

1. Alatrakchi N, Graham CS, He Q, Serman KE, Koziel MJ. CD8 cell responses to hepatitis C virus in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis. 2005;191:702-9.
2. Alter MJ. Epidemiology of hepatitis C in the west. Semin Liver Dis. 1995;15:5-14.
3. Bagaglio S, Ghezzi S, Lodrini S, Vicenzi E, Santagostino E, Carminati G. Hepatitis C virus infection in HIV-infected long term non progressors [abstract]. J Hepatol. 2003;38 Suppl 2:125.
4. Benito JM, López M, Soriano V. The role of CD8+ T-cell response in HIV infection. AIDS Rev. 2004;6(2):79-88.
5. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C, AIDS Clinical Trials Group A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV co-infected persons. N Engl J Med. 2004;351:451-9.
6. Di Bisceglie AM. Hepatitis C. Lancet. 1998;351:351-5.
7. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P. The influence of human immunodeficiency virus co-infection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193-9.
8. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in co-infection. Am J Med. 1999;107:79s-84s.
9. Dorucci M, Pezzotti P, Phillips NA, Lepri AC, Rezza G (for the Italian Seroconversion Study). Co-infection of hepatitis C virus with immunodeficiency virus and progression to AIDS. J Infect Dis. 1995;172:1503-8.
10. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166-72.
11. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, Horsburgh R, Craven D, Sherman KE, Koziel MJ. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology. 2004;40:125-32.
12. Greub G, Ledengerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co-infection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-5.
13. Halfon P, Ouzan D, Cattan L, Cacoub P. The diagnostic tools of hepatitis C virus infections. Presse Med. 2004;33:538-41.
14. Hess C, Altfeld M, Thomas SY, Addo MM, Rosenber ES, Allen TM, Draenert R, Eldrige RL, van Lunzen J, Stellbrink HJ, Walker BD, Luster AD. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet. 2004;363:863-6.
15. Jackson JB, Parsons JS, Nichols LS, Knoble N, Kennedy S, Piwowar EM. Detection of human immunodeficiency virus type 1 (HIV-1) antibody by western blotting and HIV-1 DNA by PCR in patients with AIDS. J Clin Microbiol. 1997;35:1118-21.
16. Kim AY, Lauer GM, Ouchi K, Addo MM, Lucas M, Schulze Zur Wiesch J, Timm J, Boczanowski M, Duncan JE, Wurcel AG, Casson D, Chung RT, Draenert R, Klenerman P, Walker BD. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 2005;105:1170-8.
17. Laurence J. T-cell subsets in health, infectious disease, and idiopathic CD4 T lymphocytopenia. Ann Intern Med. 1993;119:55-62.
18. Lessens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis. 1999;179:1254-8.
19. Miller MF, Haley C, Koziel MJ, Rowley CR. Impact of hepatitis C virus on immune restoration in HIV infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005;41:713-20.
20. Myers RP, Benhamou Y, Boche M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004;18:75-9.
21. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, Grappin M, Buisson M, Waldner A, Portier H, Chavanet P. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS. 1998;12:381-8.
22. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J, EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. Infect Dis 2005;192:992-1002.
23. Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A, Bouwer HG, Hinrichs DJ. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002;35:190-8.
24. Sabin CA, Telfer P, Phillips NA, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis. 1997;175:164-8.
25. Shaw GM. Biology of human immunodeficiency viruses. In: Goldman L, Ausiello D, editors. Cecil textbook of medicine. 22nd ed. Philadelphia: Saunders; 2004. p.2139-44.
26. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol. 1999;31 Suppl 1:119-23.
27. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS. 1999;13:539-46.
28. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, Dieterich D, Hatzakis A, Rockstroh J. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18:1-12.
29. Staples CT, Rimland D, Dudas D. Hepatitis C in the HIV Atlanta VA Cohort Study (HAVACS): the effect of co-infection on survival. Clin Infect Dis. 1999;29:150-4.
30. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30:s77-s84.
31. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199-206.
32. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-50.
33. World Health Organization. Hepatitis C global prevalence (update). Wkly Epidemiol Rec. 2000;75:17-28.
34. Wright TL, Hollander H, Pu X, Held MJ, Lipson P, Quan S, Polito A, Thaler MM, Bacchetti P, Scharschmidt BF. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology. 1994;20:1152-5.